comparemela.com
Home
Live Updates
CSL Says Cardiovascular Drug CSL112 Didnt Meet Efficacy Endpoint After Study : comparemela.com
CSL Says Cardiovascular Drug CSL112 Didn't Meet 'Efficacy Endpoint' After Study
By Mike Cherney SYDNEY--Australia-based pharmaceutical company CSL said its Phase 3 study into whether its CSL112 drug reduced the risk of cardiovascular...
Related Keywords
Sydney
,
New South Wales
,
Australia
,
Mike Cherney
,
,
Article Normal
,
Biotechnology Services
,
Pharmaceuticals
,
Cardiovascular Drugs
,
Healthcare Life Sciences
,
Biopharmaceuticals
,
Specialized Drugs Medications
,
New Products Services
,
Research Development
,
Corporate Industrial News
,
Products Services
,
New Product Service Testing
,
Cardiovascular Conditions
,
Political General News
,
Health
,
Medical Conditions
,
Content Types
,
Factiva Filters
,
C Amp Ampe Industry News Filter
,
Synd
,
Au000000csl8
,
Csl Au
,
New Products
,
Services
,
Research
,
Development
,
Corporate
,
Industrial News
,
Products
,
New Product
,
Service Testing
,
Political
,
General News
,
Healthcare
,
Life Sciences
,
Specialized Drugs
,
Medications
,
comparemela.com © 2020. All Rights Reserved.